Frontiers in Molecular Neuroscience (Oct 2018)

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients

  • Claire Bridel,
  • Anand J. C. Eijlers,
  • Wessel N. van Wieringen,
  • Marleen Koel-Simmelink,
  • Cyra E. Leurs,
  • Menno M. Schoonheim,
  • Joep Killestein,
  • Charlotte E. Teunissen

DOI
https://doi.org/10.3389/fnmol.2018.00371
Journal volume & issue
Vol. 11

Abstract

Read online

Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking.Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients.Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins.Results: In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years.Conclusions: Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.

Keywords